CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues:
Total revenues	$ 6,883	$ 2,357	$ 4,651
Operating expenses:
Research and development	118,011	82,258	53,311
General and administrative	30,914	27,195	20,488
Intangible asset impairment			3,500
Gain on fair value remeasurement of contingent consideration		(6,862)	(1,405)
Litigation settlement related loss	12,500	15,000
Total operating expenses	161,425	117,591	75,894
Operating loss	(154,542)	(115,234)	(71,243)
Investment and other income, net	13,113	2,909	505
Net loss before income tax benefit	(141,429)	(112,325)	(70,738)
Income tax benefit			227
Net loss	$ (141,429)	$ (112,325)	$ (70,511)
Basic net loss per common share (in dollars per share)	$ (2.92)	$ (2.40)	$ (1.64)
Diluted net loss per common share (in dollars per share)	$ (2.92)	$ (2.40)	$ (1.64)
Shares used in calculating basic net loss per share (in shares)	48,449	46,888	42,870
Shares used in calculating diluted net loss per share (in shares)	48,449	46,888	42,870
Comprehensive loss:
Net loss	$ (141,429)	$ (112,325)	$ (70,511)
Other comprehensive income (loss):
Unrealized gain (loss) on marketable securities	2,048	(634)	(695)
Comprehensive loss	(139,381)	(112,959)	(71,206)
Product development and licensing agreements
Revenues:
Total revenues	278	56	31
Contracts and grants
Revenues:
Total revenues	$ 6,605	$ 2,301	$ 4,620